Effects of Qualia Glutathione+ on Blood Glutathione Levels, Glutathione
Conditions
Brief summary
This is a randomized, double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be randomized to one of three study arms: Qualia Glutathione+ version 1, Qualia Glutathione+ version 2, or placebo. Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period. The primary outcome is the change in blood glutathione levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related quality of life, fatigue, and cognitive functioning (PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a, PROMIS Cognitive Function - Short Form 8a), evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Interventions
DIETARY_SUPPLEMENTQualia Glutathione+ version 1
Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences
DIETARY_SUPPLEMENTQualia Glutathione+ version 2
Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences
DIETARY_SUPPLEMENTPlacebo
Rice flour
Sponsors
Qualia Life Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Provide voluntary, written, informed consent to participate in the study * Agree to provide a valid cell phone number and are willing to receive communications through text * Can read and write English * Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly * Willing to complete questionnaires, records, and diaries associated with the study. * Healthy male and female participants aged 45-75 years * Willing to go to a local blood draw location for a Whole Blood Total Glutathione measurement (baseline and Day 20) * Willing to avoid starting new or stopping any existing dietary supplements throughout the study
Exclusion criteria
* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial * Known food intolerances/allergy to any ingredients in the product * Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer * Having had a significant cardiovascular event in the past 6 months * Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines * On immunosuppressive therapy * Adults lacking capacity to consent * Active Smokers * Diagnosed Diabetics
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Glutathione levels from baseline to Day 20 | 0-20 days | To assess between-group differences in the change in blood Total Glutathione levels from baseline to Day 20 following supplementation with Qualia Glutathione version 1 versus placebo and Qualia Glutathione version 2 versus placebo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| within-group differences in the change in blood Glutathione levels | baseline to day 20 | To assess within-group differences in the change in blood Glutathione levels |
| Safety and Tolerability survey | baseline to days 7, 14 and 20 | To evaluate side effect profiles using a custom Safety and Tolerability survey. |
| between-group differences in blood Total Glutathione levels | baseline to day 20 | To assess the between-group differences in blood Total Glutathione levels from baseline to Day 20 following supplementation between Qualia Glutathione version 1 and Qualia Glutathione version 2. |
| PROMIS Short Form v1.0 - Fatigue 10a | baseline to days 7, 14 and 20 | The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The fatigue short forms are universal rather than disease-specific. All assess fatigue over the past seven days. Raw Score Minimum and Maximum: 10-50 the lower the better |
| PROMIS Cognitive Function - Short Form 8a | baseline to days 7, 14 and 20 | The PROMIS Cognitive Function v2.0 - Short Form 8a is an 8-item self-report questionnaire designed to assess perceived cognitive function over the past seven days. It measures difficulties in areas such as forming thoughts, concentration, attention, thinking speed, memory, and the ability to shift between tasks. \- Raw Score Minimum and Maximum: 8-40 - The higher the score, the better |
| PROMIS Global Health-10 | baseline to days 7, 14 and 20 | The PROMIS® Global Health Scale v1.2 (also known as the PROMIS-GH or PROMIS-10) is a 10-item, non-disease-specific questionnaire for adults to assess general physical and mental health. It yields two main scores, a Global Physical Health (GPH) T-score and a Global Mental Health (GMH) T-score, derived from four items each, to understand overall health perceptions. The scale is widely translated and free for use in clinical and research settings. * Raw Score Minimum and Maximum: 0-20 * The higher the score, the better |
Countries
United States
Contacts
Primary ContactWilliam Scuba
Outcome results
None listed